Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Andexanet alfa - Alexion AstraZeneca Rare Disease

Next Previous
Drug Profile

Andexanet alfa - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN 2070; ANDEXXA; AndexXa; Coagulation factor Xa (recombinant), inactivated-zhzo; IndexXa; Ondexa; Ondexxya; PRT-064445; PRT-4445; PRT-44545; r-antidote; Recombinant factor-Xa-Portola; rfXa-inhibitor-antidote

Latest Information Update: 05 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Portola Pharmaceuticals
  • Developer Alexion AstraZeneca Rare Disease
  • Class Antidotes; Antihaemorrhagics; Disulfides; Recombinant proteins
  • Mechanism of Action Blood coagulation stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemorrhage

Most Recent Events

  • 05 Feb 2026 AstraZeneca, Parexel initiate a phase I pharmacokinetics trial in Healthy volunteers in Germany and United Kingdom (IV, Injection, Infusion) (NCT07312851)
  • 31 Dec 2025 AstraZeneca in collaboration with Parexel plans a phase I posology and interaction trial in Healthy volunteers in Germany and United Kingdom (IV, Injection, Infusion) in January 2026 (NCT07312851)
  • 23 Oct 2024 AstraZeneca withdraws a phase III trial for Haemorrhage due to a business decision (IV) (NCT05926349)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top